Trade Repro Med Systems, Inc. - KRMD CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
KORU Medical Systems Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 2.68 |
Open* | 2.65 |
1-Year Change* | 19.37% |
Day's Range* | 2.51 - 2.65 |
52 wk Range | 1.82-4.48 |
Average Volume (10 days) | 44.58K |
Average Volume (3 months) | 972.01K |
Market Cap | 169.68M |
P/E Ratio | -100.00K |
Shares Outstanding | 45.61M |
Revenue | 29.04M |
EPS | -0.19 |
Dividend (Yield %) | N/A |
Beta | 0.41 |
Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 29, 2023 | 2.68 | -0.08 | -2.90% | 2.76 | 2.77 | 2.62 |
Sep 28, 2023 | 2.75 | 0.09 | 3.38% | 2.66 | 2.76 | 2.66 |
Sep 27, 2023 | 2.73 | 0.05 | 1.87% | 2.68 | 2.75 | 2.66 |
Sep 26, 2023 | 2.72 | 0.05 | 1.87% | 2.67 | 2.72 | 2.65 |
Sep 25, 2023 | 2.77 | 0.01 | 0.36% | 2.76 | 2.79 | 2.70 |
Sep 22, 2023 | 2.78 | 0.02 | 0.72% | 2.76 | 2.86 | 2.75 |
Sep 21, 2023 | 2.88 | -0.04 | -1.37% | 2.92 | 3.04 | 2.88 |
Sep 20, 2023 | 3.04 | 0.26 | 9.35% | 2.78 | 3.07 | 2.76 |
Sep 19, 2023 | 2.81 | 0.29 | 11.51% | 2.52 | 2.84 | 2.52 |
Sep 18, 2023 | 2.64 | 0.10 | 3.94% | 2.54 | 2.65 | 2.54 |
Sep 15, 2023 | 2.62 | 0.04 | 1.55% | 2.58 | 2.67 | 2.49 |
Sep 14, 2023 | 2.65 | 0.14 | 5.58% | 2.51 | 2.66 | 2.51 |
Sep 13, 2023 | 2.52 | -0.08 | -3.08% | 2.60 | 2.60 | 2.49 |
Sep 12, 2023 | 2.56 | -0.02 | -0.78% | 2.58 | 2.60 | 2.51 |
Sep 11, 2023 | 2.58 | 0.05 | 1.98% | 2.53 | 2.67 | 2.53 |
Sep 8, 2023 | 2.55 | 0.03 | 1.19% | 2.52 | 2.60 | 2.50 |
Sep 7, 2023 | 2.60 | 0.12 | 4.84% | 2.48 | 2.72 | 2.41 |
Sep 6, 2023 | 2.49 | -0.02 | -0.80% | 2.51 | 2.53 | 2.40 |
Sep 5, 2023 | 2.52 | -0.08 | -3.08% | 2.60 | 2.61 | 2.51 |
Sep 1, 2023 | 2.59 | -0.01 | -0.38% | 2.60 | 2.64 | 2.50 |
Repro Med Systems, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, November 7, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Q3 2023 KORU Medical Systems Inc Earnings Release Q3 2023 KORU Medical Systems Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 27.896 | 23.4902 | 24.1765 | 23.1626 | 17.3537 |
Revenue | 27.896 | 23.4902 | 24.1765 | 23.1626 | 17.3537 |
Cost of Revenue, Total | 12.5271 | 9.7206 | 9.24036 | 8.30881 | 6.54325 |
Gross Profit | 15.369 | 13.7696 | 14.9361 | 14.8538 | 10.8105 |
Total Operating Expense | 38.6769 | 30.5197 | 25.4312 | 22.5769 | 16.1892 |
Selling/General/Admin. Expenses, Total | 20.6065 | 17.8623 | 12.0283 | 9.77174 | 9.09557 |
Research & Development | 4.95622 | 2.47367 | 1.29675 | 0.74048 | 0.24112 |
Depreciation / Amortization | 0.58714 | 0.46313 | 0.4186 | 0.34023 | 0.30926 |
Operating Income | -10.7809 | -7.02953 | -1.25478 | 0.58568 | 1.16454 |
Interest Income (Expense), Net Non-Operating | 0.10572 | -0.01583 | 0.04394 | 0.06291 | 0.00748 |
Net Income Before Taxes | -10.6752 | -6.36444 | -1.19426 | 0.69642 | 1.17695 |
Net Income After Taxes | -8.66114 | -4.56282 | -1.21206 | 0.56435 | 0.91057 |
Net Income Before Extra. Items | -8.66114 | -4.56282 | -1.21206 | 0.56435 | 0.91057 |
Net Income | -8.66114 | -4.56282 | -1.21206 | 0.56435 | 0.91057 |
Income Available to Common Excl. Extra. Items | -8.66114 | -4.56282 | -1.21206 | 0.56435 | 0.91057 |
Income Available to Common Incl. Extra. Items | -8.66114 | -4.56282 | -1.21206 | 0.56435 | 0.91057 |
Diluted Net Income | -8.66114 | -4.56282 | -1.21206 | 0.56435 | 0.91057 |
Diluted Weighted Average Shares | 45.0021 | 44.385 | 41.9297 | 39.0613 | 38.9216 |
Diluted EPS Excluding Extraordinary Items | -0.19246 | -0.1028 | -0.02891 | 0.01445 | 0.02339 |
Diluted Normalized EPS | -0.19246 | -0.10282 | 0.00877 | 0.08432 | 0.0233 |
Total Extraordinary Items | |||||
Dividends per Share - Common Stock Primary Issue | |||||
Gain (Loss) on Sale of Assets | 0 | 0.00101 | 0.01659 | 0.04783 | 0.00493 |
Unusual Expense (Income) | 0 | 2.44721 | 3.41568 | ||
Other, Net | 0 | 0.67991 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total revenue | 7.39261 | 7.34468 | 7.7604 | 6.54663 | 6.24433 |
Revenue | 7.39261 | 7.34468 | 7.7604 | 6.54663 | 6.24433 |
Cost of Revenue, Total | 3.24557 | 3.26654 | 3.43804 | 3.20046 | 2.62203 |
Gross Profit | 4.14704 | 4.07814 | 4.32236 | 3.34617 | 3.6223 |
Total Operating Expense | 10.4494 | 9.8561 | 9.28988 | 10.1601 | 9.37085 |
Selling/General/Admin. Expenses, Total | 5.42588 | 4.75992 | 4.82535 | 5.53002 | 5.49121 |
Research & Development | 1.56487 | 1.64198 | 0.86215 | 1.30373 | 1.14836 |
Depreciation / Amortization | 0.21312 | 0.18766 | 0.16434 | 0.12588 | 0.10925 |
Operating Income | -3.05682 | -2.51142 | -1.52948 | -3.61346 | -3.12652 |
Interest Income (Expense), Net Non-Operating | 0.12482 | 0.10003 | 0.03242 | -0.01814 | -0.0086 |
Gain (Loss) on Sale of Assets | -0.05628 | 0 | 0 | 0 | 0 |
Net Income Before Taxes | -2.98829 | -2.41139 | -1.49706 | -3.6316 | -3.13511 |
Net Income After Taxes | -2.41089 | -1.97673 | -1.22556 | -2.92134 | -2.53751 |
Net Income Before Extra. Items | -2.41089 | -1.97673 | -1.22556 | -2.92134 | -2.53751 |
Net Income | -2.41089 | -1.97673 | -1.22556 | -2.92134 | -2.53751 |
Income Available to Common Excl. Extra. Items | -2.41089 | -1.97673 | -1.22556 | -2.92134 | -2.53751 |
Income Available to Common Incl. Extra. Items | -2.41089 | -1.97673 | -1.22556 | -2.92134 | -2.53751 |
Diluted Net Income | -2.41089 | -1.97673 | -1.22556 | -2.92134 | -2.53751 |
Diluted Weighted Average Shares | 45.4876 | 45.3762 | 45.0382 | 44.9219 | 44.668 |
Diluted EPS Excluding Extraordinary Items | -0.053 | -0.04356 | -0.02721 | -0.06503 | -0.05681 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.0522 | -0.04356 | -0.02721 | -0.06503 | -0.05681 |
Unusual Expense (Income) | |||||
Other, Net |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 29.8016 | 37.3212 | 37.5258 | 11.8813 | 9.03305 |
Cash and Short Term Investments | 17.4083 | 25.3349 | 27.3153 | 5.87093 | 5.25673 |
Cash & Equivalents | 17.4083 | 25.3349 | 27.3153 | 5.87093 | 3.7388 |
Short Term Investments | 0 | 1.51793 | |||
Total Receivables, Net | 4.53128 | 4.31111 | 2.57295 | 3.23452 | 1.42585 |
Accounts Receivable - Trade, Net | 3.55888 | 3.59289 | 2.57295 | 3.23452 | 1.42585 |
Total Inventory | 6.40487 | 6.10634 | 6.82977 | 2.38848 | 2.10388 |
Prepaid Expenses | 1.45723 | 1.56882 | 0.80778 | 0.3874 | 0.24659 |
Total Assets | 42.3324 | 41.293 | 39.9189 | 13.8819 | 10.545 |
Property/Plant/Equipment, Total - Net | 7.67352 | 1.202 | 1.40447 | 0.98558 | 0.85878 |
Intangibles, Net | 0.78718 | 0.80881 | 0.84359 | 0.80714 | 0.63216 |
Other Long Term Assets, Total | 4.07011 | 1.96107 | 0.14509 | 0.20782 | 0.02105 |
Total Current Liabilities | 6.95894 | 4.79198 | 3.6664 | 2.40629 | 1.58423 |
Accounts Payable | 2.3918 | 1.22753 | 0.62492 | 0.57266 | 0.4535 |
Accrued Expenses | 3.77817 | 2.96586 | 3.03884 | 1.82834 | 1.12697 |
Notes Payable/Short Term Debt | 0.4333 | 0.50858 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.25734 | 0.09 | 0 | 0.00376 | |
Total Liabilities | 11.0065 | 4.79198 | 3.76196 | 2.64578 | 1.58423 |
Total Long Term Debt | 0.39428 | 0 | 0 | 0.00265 | 0 |
Deferred Income Tax | 0 | ||||
Other Liabilities, Total | 3.65326 | 0 | 0.09555 | 0.23685 | 0 |
Total Equity | 31.326 | 36.5011 | 36.157 | 11.2361 | 8.96081 |
Common Stock | 0.48862 | 0.48044 | 0.4668 | 0.4224 | 0.40933 |
Additional Paid-In Capital | 44.2521 | 40.7743 | 35.881 | 6.29307 | 4.59521 |
Retained Earnings (Accumulated Deficit) | -9.57121 | -0.91007 | 3.65275 | 4.86482 | 4.30047 |
Treasury Stock - Common | -3.84356 | -3.84356 | -3.84356 | -0.3442 | -0.3442 |
Total Liabilities & Shareholders’ Equity | 42.3324 | 41.293 | 39.9189 | 13.8819 | 10.545 |
Total Common Shares Outstanding | 45.4414 | 44.6237 | 43.2596 | 39.5026 | 38.1957 |
Property/Plant/Equipment, Total - Gross | 10.4679 | 3.51403 | 3.39009 | 2.80482 | |
Accumulated Depreciation, Total | -2.7944 | -2.31203 | -1.98562 | -1.81924 | |
Current Port. of LT Debt/Capital Leases | 0.09834 | 0 | 0.00265 | 0.0053 | |
Capital Lease Obligations | 0.39428 | 0 | 0.00265 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 25.2147 | 29.8016 | 30.7423 | 30.9683 | 33.9313 |
Cash and Short Term Investments | 12.2249 | 17.4083 | 16.4413 | 18.2656 | 22.5772 |
Cash & Equivalents | 12.2249 | 17.4083 | 16.4413 | 18.2656 | 22.5772 |
Total Receivables, Net | 5.17927 | 4.53128 | 5.75619 | 4.76556 | 3.82547 |
Accounts Receivable - Trade, Net | 4.16451 | 3.55888 | 5.07008 | 4.08476 | 3.1454 |
Total Inventory | 6.63842 | 6.40487 | 6.88416 | 6.77151 | 6.01774 |
Prepaid Expenses | 1.1721 | 1.45723 | 1.66066 | 1.16567 | 1.51085 |
Total Assets | 38.254 | 42.3324 | 42.6658 | 42.4613 | 43.4276 |
Property/Plant/Equipment, Total - Net | 7.61294 | 7.67352 | 7.51538 | 7.36317 | 6.07255 |
Property/Plant/Equipment, Total - Gross | 9.8376 | 10.4679 | 10.166 | 9.86705 | 8.46595 |
Accumulated Depreciation, Total | -2.22466 | -2.7944 | -2.65064 | -2.50387 | -2.39339 |
Intangibles, Net | 0.78253 | 0.78718 | 0.79853 | 0.79178 | 0.79534 |
Other Long Term Assets, Total | 4.64385 | 4.07011 | 3.6096 | 3.3381 | 2.62844 |
Total Current Liabilities | 4.52422 | 6.95894 | 6.16749 | 5.73013 | 4.71262 |
Accounts Payable | 1.50312 | 2.3918 | 1.36561 | 2.38986 | 1.26798 |
Accrued Expenses | 2.44146 | 3.77817 | 3.73519 | 3.03327 | 3.0734 |
Notes Payable/Short Term Debt | 0.2184 | 0.4333 | 0.64473 | 0 | 0.25561 |
Current Port. of LT Debt/Capital Leases | 0.09969 | 0.09834 | 0.06447 | 0.0665 | |
Total Liabilities | 8.45768 | 11.0065 | 10.1741 | 9.83999 | 8.62654 |
Total Long Term Debt | 0.36884 | 0.39428 | 0.26554 | 0.28196 | 0 |
Other Liabilities, Total | 3.56462 | 3.65326 | 3.74102 | 3.8279 | 3.91392 |
Total Equity | 29.7963 | 31.326 | 32.4917 | 32.6213 | 34.8011 |
Common Stock | 0.48961 | 0.48862 | 0.48657 | 0.48408 | 0.48121 |
Additional Paid-In Capital | 45.1324 | 44.2521 | 43.4432 | 42.3498 | 41.611 |
Retained Earnings (Accumulated Deficit) | -11.9821 | -9.57121 | -7.59448 | -6.36892 | -3.44758 |
Treasury Stock - Common | -3.84356 | -3.84356 | -3.84356 | -3.84356 | -3.84356 |
Total Liabilities & Shareholders’ Equity | 38.254 | 42.3324 | 42.6658 | 42.4613 | 43.4276 |
Total Common Shares Outstanding | 45.5403 | 45.4414 | 45.2365 | 44.9871 | 44.7008 |
Other Current Liabilities, Total | 0.26154 | 0.25734 | 0.35749 | 0.2405 | 0.11563 |
Capital Lease Obligations | 0.36884 | 0.39428 | 0.26554 | 0.28196 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -8.66114 | -4.56282 | -1.21206 | 0.56435 | 0.91057 |
Cash From Operating Activities | -5.40455 | -4.31951 | -0.74332 | 0.32062 | 1.47966 |
Cash From Operating Activities | 0.58714 | 0.46313 | 0.4186 | 0.34023 | 0.30926 |
Deferred Taxes | -2.02623 | -1.81598 | 0.06297 | -0.18678 | -0.02314 |
Non-Cash Items | 3.29197 | 2.70655 | 2.92099 | 1.1484 | 0.2991 |
Cash Taxes Paid | 0 | 0.0019 | 0.32198 | 0.13088 | 0.378 |
Cash Interest Paid | 0.02849 | 0.01324 | 0.02774 | 0.00034 | 0 |
Changes in Working Capital | 1.40371 | -1.11038 | -2.93381 | -1.54558 | -0.01613 |
Cash From Investing Activities | -2.80157 | -0.36617 | -1.03615 | 1.31021 | -1.72982 |
Capital Expenditures | -2.80157 | -0.37523 | -1.06115 | -0.42554 | -0.48117 |
Other Investing Cash Flow Items, Total | 0 | 0.00907 | 0.025 | 1.73575 | -1.24866 |
Cash From Financing Activities | 0.27949 | 2.70528 | 23.2238 | 0.5013 | 0.01443 |
Financing Cash Flow Items | -0.07529 | 0.50858 | 0 | -0.00282 | -0.03682 |
Issuance (Retirement) of Stock, Net | 0.40662 | 2.19935 | 23.2291 | 0.5089 | 0.05125 |
Net Change in Cash | -7.92663 | -1.9804 | 21.4444 | 2.13213 | -0.23573 |
Issuance (Retirement) of Debt, Net | -0.05185 | -0.00265 | -0.0053 | -0.00478 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -2.41089 | -8.66114 | -6.68442 | -5.45886 | -2.53751 |
Cash From Operating Activities | -4.66058 | -5.40455 | -6.74101 | -4.62531 | -1.75207 |
Cash From Operating Activities | 0.21312 | 0.58714 | 0.39948 | 0.23513 | 0.10925 |
Deferred Taxes | -0.5774 | -2.02623 | -1.57957 | -1.30807 | -0.5976 |
Non-Cash Items | 0.932 | 3.29197 | 2.57913 | 1.57915 | 0.83756 |
Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Cash Interest Paid | 0.01233 | 0.02849 | 0.0157 | 0.0062 | 0.00443 |
Changes in Working Capital | -2.81742 | 1.40371 | -1.45564 | 0.32733 | 0.43623 |
Cash From Investing Activities | -0.28384 | -2.80157 | -2.5777 | -1.92883 | -0.7526 |
Capital Expenditures | -0.28384 | -2.80157 | -2.5777 | -1.92883 | -0.7526 |
Other Investing Cash Flow Items, Total | 0 | 0 | 0 | 0 | |
Cash From Financing Activities | -0.23897 | 0.27949 | 0.42509 | -0.51519 | -0.25297 |
Issuance (Retirement) of Stock, Net | 0.40662 | 0.314 | 0 | 0 | |
Issuance (Retirement) of Debt, Net | -0.02408 | -0.05185 | -0.02506 | -0.00661 | 0 |
Net Change in Cash | -5.18339 | -7.92663 | -8.89362 | -7.06934 | -2.75764 |
Financing Cash Flow Items | -0.21489 | -0.07529 | 0.13615 | -0.50858 | -0.25297 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Repro Med Systems, Inc. Company profile
About Repro-Med Systems, Inc.
Repro Med Systems, Inc. is a medical technology company, which is focused on the developing, manufacturing, and commercializing of specialty infusion solutions. The Company designs, manufactures, and markets medical devices, primarily for the ambulatory infusion market. Its development and marketing focus is primarily concentrated on its mechanical infusion products. The Company's products include the FREEDOM Infusion Systems, which consist of the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgHFlo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The FREEDOM System operates at a lower pressure and maintains a balance between what a patient’s subcutaneous tissues can absorb and what the system delivers. The Company performs product assembly, calibration, pre- and post-assembly quality control inspection and testing, and final packaging for all its products at its Chester, New York facility.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Repro-Med Systems, Inc. revenues decreased 3% to $23.5M. Net loss increased from $1.2M to $4.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Selling, general and administrative increase of 49% to $17.9M (expense), Research and development increase of 91% to $2.5M (expense).
Equity composition
Common Stock $.01 Par, 11/10, 50M auth., 38,811,667 issd., less 2,275,000 shs. in Treas. @ $142K. Insiders control approx. 27.87 .Public Offering 11/82, $4.8M shares @ $.25 by State Street Securities. Preferred Stock 8% Cumulative $.01 Par, 2M auth., 10,000 issd.
Industry: | Medical Equipment, Supplies & Distribution (NEC) |
100 Corporate Drive
MAHWAH
NEW JERSEY 07430
US
Income Statement
- Annual
- Quarterly
News

How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com